

IN THE CLAIMS

Claim 1. (Currently Amended) A method for treating ~~or preventing~~ a neoplasia disorder in a mammal in need of such treatment ~~or prevention~~, which method comprises administering to said mammal a therapeutically-effective amount of a ~~combination of~~ the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]3-thiomorpholinecarboxamide and ~~one or more antineoplastic agents, wherein said an~~ antineoplastic agents ~~are~~ selected from the group consisting of irinotecan and topotecan and a combination thereof.

Claim 2. (Currently Amended) The method of Claim 1 wherein the matrix metalloproteinase inhibitor and antineoplastic agent are combination is administered in a sequential manner.

Claim 3. (Currently Amended) The method of Claim 1 wherein the matrix metalloproteinase inhibitor and antineoplastic agent are combination is administered in a substantially simultaneous manner.

Claims 4.-10. (Previously Canceled)

Claim 11. (Original) The method of Claim 1 wherein the antineoplastic agent is irinotecan.

Claim 12.-20 (Previously Canceled)

Claim 21. (Original) The method of Claim 1 wherein the antineoplastic agent is topotecan.

Claims 22-42. (Previously Canceled)

Claim 43. (Original) The method of Claim 1 wherein the neoplasia is selected from the group consisting of acral lentiginous melanoma, actinic keratoses, adenocarcinoma, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, astrocytic tumors, Bartholin gland carcinoma, basal cell carcinoma, bronchial gland carcinomas, capillary carcinoids, carcinoma, carcinosarcoma, cavernous, cholangiocarcinoma, chondrosarcoma, choroid plexus papilloma/carcinoma, clear cell carcinoma, cystadenoma, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, ependymal, epithelioid, Ewing's sarcoma, fibrolamellar, focal nodular hyperplasia, gastrinoma, germ cell tumors, glioblastoma, glucagonoma, hemangioblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatocellular carcinoma, insulinoma, intraepithelial neoplasia, intraepithelial squamous cell neoplasia, invasive squamous cell carcinoma, large cell carcinoma, leiomyosarcoma, lentigo maligna melanomas, malignant melanoma, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, melanoma, meningeal, mesothelial, metastatic carcinoma, mucoepidermoid carcinoma, neuroblastoma, neuroepithelial adenocarcinoma, nodular melanoma, oat cell carcinoma, oligodendroglial, osteosarcoma, pancreatic polypeptide, papillary serous adenocarcinoma, pineal cell, pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, small cell carcinoma, soft tissue carcinomas, somatostatin-secreting tumor, squamous carcinoma, squamous cell carcinoma, submesothelial, superficial spreading melanoma, undifferentiated carcinoma, uveal melanoma, verrucous carcinoma, vipoma, well differentiated carcinoma, and Wilm's tumor.

Claim 44. (Currently Amended) A method for treating ~~or preventing~~ a neoplasia disorder in a mammal in need of such treatment ~~or prevention~~, which method comprises administering to said mammal a therapeutically-effective amount of a ~~combination of~~ radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]3-thiomorpholinecarboxamide and ~~one or more antineoplastic agents~~, wherein said an antineoplastic agent is selected from the group consisting of irinotecan and topotecan and a combination thereof.

Claim 45. (Currently Amended) The method of Claim 44 wherein the matrix metalloproteinase inhibitor and antineoplastic agent are combination is administered in a sequential manner.

Claim 46. (Currently Amended) The method of Claim 44 wherein the matrix metalloproteinase inhibitor and antineoplastic agent are combination is administered in a substantially simultaneous manner.

Claims 47.-53. (Previously Canceled)

Claim 54. (Original) The method of Claim 44 wherein the antineoplastic agent is irinotecan.

Claims 55.-70. (Previously Canceled)

Claim 71. (Original) The method of Claim 44 wherein the neoplasia is selected from the group consisting of lung cancer, breast cancer, gastrointestinal cancer, bladder cancer, head and neck cancer and cervical cancer.

Claims 72.-85. (Previously Canceled)

Claim 86. (Original) The method of Claim 44 wherein the neoplasia is selected from the group consisting of acral lentiginous melanoma, actinic keratoses, adenocarcinoma, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, astrocytic tumors, Bartholin gland carcinoma, basal cell carcinoma, bronchial gland carcinomas, capillary carcinoids, carcinoma, carcinosarcoma, cavernous, cholangiocarcinoma, chondrosarcoma, choroid plexus papilloma/carcinoma, clear cell carcinoma, cystadenoma, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, ependymal, epithelioid, Ewing's sarcoma, fibrolamellar, focal nodular hyperplasia, gastrinoma, germ cell tumors, glioblastoma, glucagonoma, hemangioblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatocellular carcinoma, insulinoma, intraepithelial neoplasia, intraepithelial squamous cell neoplasia, invasive squamous cell carcinoma, large cell carcinoma, leiomyosarcoma, lentigo maligna melanomas, malignant melanoma, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, melanoma, meningeal, mesothelial, metastatic carcinoma, mucoepidermoid carcinoma, neuroblastoma, neuroepithelial adenocarcinoma, nodular melanoma, oat cell carcinoma, oligodendroglial, osteosarcoma, pancreatic polypeptide, papillary serous adenocarcinoma, pineal cell, pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, small cell carcinoma, soft tissue carcinomas, somatostatin-secreting tumor, squamous carcinoma, squamous cell carcinoma, submesothelial, superficial spreading melanoma, undifferentiated carcinoma, uveal melanoma, verrucous carcinoma, vipoma, well differentiated carcinoma, and Wilm's tumor.

Claim 87. (Previously Presented) A combination comprising the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-

---

pyridinyloxy)phenyl]sulfonyl]3-thiomorpholinecarboxamide and one or more antineoplastic agents, wherein said antineoplastic agents are selected from the group consisting of irinotecan and topotecan.

Claims 88.-106. (Previously Canceled)

Claim 107. (Currently Amended) A method for treating ~~or preventing~~ a neoplasia disorder of the lung in a mammal in need of such treatment ~~or prevention~~, which method comprises administering to said mammal a therapeutically-effective amount of ~~a combination of~~ the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]3-thiomorpholinecarboxamide and ~~one or more antineoplastic agents, wherein said~~ an antineoplastic agents are selected from the group consisting of irinotecan and topotecan and a combination thereof.

Claim 108. (Currently Amended) A method for treating ~~or preventing~~ a neoplasia disorder of the lung in a mammal in need of such treatment ~~or prevention~~, which method comprises administering to said mammal a therapeutically-effective amount of ~~a combination of~~ radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]3-thiomorpholinecarboxamide and ~~one or more antineoplastic agents, wherein said~~ an antineoplastic agents are selected from the group consisting of irinotecan and topotecan and a combination thereof.

Claim 109. (Previously Canceled)

Claim 110. (New) The method of claim 1 wherein the neoplasia disorder is lung cancer.

Claim 111. (New) The method of claim 1 wherein the neoplasia disorder is colorectal cancer.

Claim 112. (New) The method of claim 1 wherein the neoplasia disorder is breast cancer.

Claim 113. (New) The method of claim 1 wherein the neoplasia disorder is prostate cancer.

Claim 114. (New) The method of claim 1 wherein the neoplasia disorder is bladder cancer.

Claim 115. (New) The method of claim 1 wherein the neoplasia disorder is ovary cancer.

Claim 116. (New) The method of claim 1 wherein the neoplasia disorder is cervical cancer.

Claim 117. (New) The method of claim 1 wherein the neoplasia disorder is gastrointestinal cancer.

Claim 118. (New) The method of claim 1 wherein the neoplasia disorder is head and neck cancer.

Claim 119. (New) The method of claim 44 wherein the neoplasia disorder is lung cancer.

Claim 120. (New) The method of claim 44 wherein the neoplasia disorder is colorectal cancer.

Claim 121. (New) The method of claim 44 wherein the neoplasia disorder is breast cancer.

Claim 122. (New) The method of claim 44 wherein the neoplasia disorder is prostate cancer.

Claim 123. (New) The method of claim 44 wherein the neoplasia disorder is bladder cancer.

Claim 124. (New) The method of claim 44 wherein the neoplasia disorder is ovary cancer.

Claim 125. (New) The method of claim 44 wherein the neoplasia disorder is cervical cancer.

Claim 126. (New) The method of claim 44 wherein the neoplasia disorder is gastrointestinal cancer.

Claim 127. (New) The method of claim 44 wherein the neoplasia disorder is head and neck cancer.

Claim 128. (New) The method of claim 107 wherein the antineoplastic agent is irinotecan.

Claim 129. (New) The method of claim 108 wherein the antineoplastic agent is irinotecan.

Claim 130. (New) The method of claim 107 wherein the antineoplastic agent is topotecan.

Claim 131. (New) The method of claim 108 wherein the antineoplastic agent is topotecan.

Claim 132. (New) The combination of claim 87 wherein the antineoplastic agent is irinotecan.

Claim 133. (New) The method of claim 87 wherein the antineoplastic agent is topotecan.